Hypera S.A.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HYPMY | ROVI.MC | H5P.F | OFSA3.SA | JENBURPH.BO | PBH | |
|---|---|---|---|---|---|---|
| Market cap | 2.75B | 3.47B | 4.24B | 1.34B | 4.18B | 2.52B |
| P/E (TTM) | 7.5 | 18.7 | 13.6 | 5.7 | 12.7 | 14.9 |
| Forward P/E | — | 20.7 | — | 12.0 | 27.2 | 10.4 |
| Price/book | 0.9 | 5.0 | 2.0 | 1.6 | 2.1 | 1.3 |
| Dividend yield | 5.19% | 1.50% | 3.46% | 5.18% | 2.30% | — |
| 1-year change | −17.46% | +15.91% | +20.00% | +10.32% | −23.57% | −13.17% |
| Today | +1.83% | +6.43% | −2.38% | +1.34% | +1.83% | +7.55% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All HYPMY news ›Hypera S.A. 2026 Q3 - Results - Earnings Call Presentation
2026-10-30. The following slide deck was published by Hypera S.A. The following slide deck was published by Hypera S.A. in conjunction with their 2026 Q3 earnings call.
Hypera S.A. (HYPMY) Q3 2026 Earnings Call Transcript
Hypera S.A. (HYPMY) Q3 2026 Earnings Call October 28, 2026 10:00 AM EDT Breno Pires de Oliveira - Chief Executive OfficerRamon Frutuoso Silva - CFO & Investor Relation Officer Good morning, ladies and gentlemen. Welcome to Hypera Pharma's…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- seekingalpha.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.